IBC Ab002
Alternative Names: IBC-Ab002Latest Information Update: 17 Jul 2026
At a glance
- Originator ImmunoBrain Checkpoint
- Class Antidementias; Monoclonal antibodies; Neuroprotectants
- Mechanism of Action Antibody-dependent cell cytotoxicity; B7-H1 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alzheimer's disease
- Research Neurodegenerative disorders
- Discontinued Amyotrophic lateral sclerosis; Frontotemporal dementia
Most Recent Events
- 14 Jul 2026 Efficacy data from a phase I trial in Alzheimer's disease released by ImmunoBrain Checkpoint
- 19 Mar 2026 Efficacy and advers event data from a phase I trial in Alzheimer's disease released by ImmunoBrain Checkpoint
- 19 Mar 2026 ImmunoBrain Checkpoint plans a phase II trial for Alzheimer's disease (Parenteral)